25-OCT-2025 6:11

OPEN STUDIES IRB REPORT

Disease
Site		 Study Study Name Open Date Number of
Active
Institutions		 Number of
Current
IRBs
 
BREAST S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 30-OCT-23 389 131
  S2212 Breast, TNBC, Neoadj Chemo + Pembro 21-JUL-23 397 155
  A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib 06-JAN-21 444 206
  A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab 03-MAY-23 404 184
  A012301 Breast, Early Stg, Tamoxifen 05-FEB-25 415 145
  MA39 BREAST, Node-Pos, Reg RT vs No Reg RT 30-MAY-18 413 159
  NRGBR007 Breast, Stg I, De-Escalation of Breast RT 07-JUN-21 405 177
  NRGBR009 Breast, EarlyStg, Adjuvant Chemo 31-AUG-23 476 194
 
CCD S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 225 92
  S2417CD Colrec Surv, Follow-up w/ CTAC site 04-AUG-25 139 33
  EAQ221CD Breast, Metastatic, Imp. Adherence 31-OCT-23 141 49
  EAQ222CD CostCOM, Cancer Patients, OOP Cost Com 29-FEB-24 102 44
 
ERLYTX S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 02-DEC-21 249 77
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 28-AUG-15 267 82
  AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult 08-MAY-17 189 115
  EAY191 ComboMATCH 06-MAR-23 329 125
  EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib 06-MAR-23 198 66
 
GI S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect 16-DEC-19 186 56
  S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs 14-OCT-21 235 75
  S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 06-MAY-24 251 89
  A021806 Pancreas, Perioperative vs Adjuvant Chemo 01-JUL-20 299 121
  A022101 Colorectal, Metastatic, Ablative Tx 10-JAN-23 154 75
  A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo 11-JAN-23 283 109
  CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad 29-FEB-24 164 50
  CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever 05-JUN-23 62 19
  EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab 17-JAN-19 250 85
  EA2192 Panc, APOLLO 29-APR-21 171 88
  EA2222 Colorectal, Stg II-III, Hep Art Infusion 19-OCT-23 70 37
  NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT 06-MAR-19 89 34
  NRGGI008 Colon, Stg III, Adj Chemo 10-MAR-22 502 201
 
GU S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum 17-SEP-18 328 138
  S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only 16-NOV-20 267 98
  S1937 Blad, Mets, Eribulin + Gem vs SOC 16-FEB-21 245 75
  S2200 pRCC, Adv, Cabo ± Atezo 19-SEP-22 186 75
  S2210 Pros, High Risk, BRCA, Neoadj Carbo 14-AUG-23 143 40
  S2312 Pros, MCRPC, Cab +/- Carb 03-SEP-24 260 86
  S2427 Blad, MIBC, RT + Pembrolizumab 04-SEP-25 68 30
  A031701 Bladder, ddGC for MIBC with DDR Tumor Alt 01-AUG-18 177 55
  A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) 12-APR-19 225 78
  A031801 GU, mRCC, Cabozantinib ± Radium-223 13-DEC-19 111 39
  A032103 Urothelial, All Stg, MRD-Based Adj Tx 09-JAN-24 359 143
  A032201 Renal Cell, High-Risk, Pembro+Tiv 05-FEB-25 339 108
  CCTG-PR26 Prostate, Cast Sensitive, Docetax 30-JAN-25 139 52
  EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT 08-SEP-17 50 18
  EA8191 Pros, Local vs Systemic Thrpy 08-OCT-20 193 62
  EA8192 Blad, High Grade UTUC, Durv + Chemo 06-MAY-21 146 50
  NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide 05-MAR-20 275 93
  NRGGU010 Pros, Parallel De-Intens & Intens Trials 03-NOV-21 458 165
  NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx 08-DEC-21 257 87
  NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy 30-JUN-22 261 87
  NRGGU013 Prostate, High-Risk, Five Fraction Radiation 13-NOV-23 315 105
 
LEUK S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O 14-DEC-20 268 93
  A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 01-JUN-17 263 86
  A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 16-NOV-18 145 49
  EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 14-OCT-20 168 55
  EA9213 T-ALL, dara-hyal for chemo refractory MRD 16-JUN-22 99 33
  MM1OAEA02 MyeloMATCH: AML, New Dx, Ven+HMA 06-JUN-24 286 98
  MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental 16-MAY-24 281 98
  MM1YACTG01 MyeloMATCH: AML, New/Young/Int, Ven+Chemo 18-JUL-24 236 82
  MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 16-MAY-24 342 135
 
LUNG S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab 28-APR-25 320 100
  S1827 SCLC, MRI Surveillance +/- PCI 10-JAN-20 345 129
  S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 03-APR-23 288 106
  S1900J MET Amplification: Amivantamab Hyaluronidase 27-SEP-24 206 75
  S1900K MET Exon 14: Tepotinib +/- Ramucirumab 18-DEC-23 268 91
  S1933 NSCLC, Stg II-III, RT + Atezo 15-JUN-20 111 36
  S2402 NSCLC, All Stg, Periop Vs Adj Tx 11-DEC-24 132 59
  S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx 08-SEP-25 74 19
  S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance 14-MAR-25 260 72
  A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO 03-JUN-20 406 165
  A082002 Lung, Adv, Systemic Tx +/- SBRT 21-DEC-21 243 70
  EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 05-APR-18 83 33
  EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 22-OCT-20 208 82
  EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno 15-FEB-24 218 87
  LUNGMAP NSCLC, Adv, Master 28-JAN-19 460 187
  NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo 10-MAY-23 326 131
 
LYMPH S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 23-FEB-23 98 39
  S2308 FL, LTB, Mosunetuzumab vs Rituximab 01-AUG-24 257 89
  A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P 30-JUL-21 186 79
  A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub 08-SEP-23 207 74
  AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy 28-APR-23 274 126
  EA4232 Lymph, Peri T Cell, Auto Stem 30-JAN-25 25 3
 
MELAN A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo 01-JUN-22 116 52
  EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim 10-SEP-15 313 99
 
MMYEL S1803 MM, Maintenance, Len vs Len/Dara 27-JUN-19 26 5
  S2005 WM, Prev. Untreated, I/R +/- Venetoclax 24-JUN-21 109 29
  S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 30-MAY-23 258 84
  S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 01-DEC-23 149 45
  EAA173 MYEL, SMM, Rd +/- Daratumumab 30-APR-19 255 102
  EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 27-OCT-20 232 81
 
MMYL A062102 MMYL, All Stg, Iberdomide Tx 04-APR-24 66 25
 
MULT S2101 Melan or HNSCC, Adv, Cabo + Nivo 14-OCT-22 184 63
 
OTHER A071701 BRAIN, Met, Geno-guided trial 15-AUG-19 150 58
  A072201 Glioblastoma, Recurrent, Block vs SOC 03-SEP-24 36 13
  A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab 18-SEP-23 3 1
  A151804 irAEs, National Biorepository to Adv Studies 31-JAN-20 144 70
  CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx 29-SEP-22 79 20
  CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy 25-MAY-18 107 43
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 252 74
  EA3191 HN, High Risk HNSCC, Adj +/- Pembro 08-JAN-21 207 67
  EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox 13-JUN-24 162 62
  NRGBN003 Mening, Grd II, Observation vs Irradiation 14-JUN-17 295 83
  NRGBN011 Brain, Lomustine + Temo vs Temo 29-NOV-21 333 115
  NRGBN013 Brain, Intact Metas, SRS vs FSRS 28-AUG-24 277 108
  NRGCC014 High Risk, Bone Meta, Radiation Tx 14-APR-25 301 99
  NRGGY022 Mult Site/Stg, Carboplat Clearance Predict 18-NOV-19 85 39
  NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE 12-AUG-22 324 133
  NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx 16-APR-24 156 59
  NRGGY036 Ovary, All Stg, Olaparib +/- Bevac 16-JAN-25 310 118
  NRGHN006 HN, Erly Stg, Biopsy vs Dissection 08-JUL-20 228 74
  NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN 27-OCT-21 287 104
  NRGHN010 HER2+ SGC, T-DM1 vs TH 30-SEP-22 133 48
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 359 109
 
PEOLC S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 249 87
  S2408 Panc Fistula Prevention, Lanreotide 14-FEB-25 87 37
 
PREV A212102 Blind Ref Set for Multicancer Early Detection 01-AUG-22 203 91
  EA2185 Panc, Impact of Panc Cyst Surveillance 16-JAN-20 116 69
  NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs 06-OCT-21 193 79
  NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO 23-JUN-20 320 137
 
SURV EAQ211 Lymph, Survivors, Health Disp. AYA 30-AUG-23 175 54
 
SXQOL S2013 I-CHECKIT: ICI toxicity risk prediction study 16-AUG-21 230 115
  S2205 ICE COMPRESS: Reduction of CIPN from Taxanes 16-MAR-23 16 30
  A211901 Cancer survivors who smoke, txt cessation 01-DEC-21 148 53
  A222004 Mult, Olanza vs Megestrol for Anorexia 15-OCT-21 0 54
  ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis 14-AUG-23 163 71
  EAQ202 Improving AYA PROs in EA Trials 28-OCT-21 45 24
  NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction 19-SEP-22 67 25
  NRGCC011 Breast, Survivors, Cog Training 02-FEB-24 260 99
  NRGCC015 E-Mindfulness After Breast Cancer 12-JUN-25 127 41